Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: The ENESTnd study

Francis J. Giles, Gianantonio Rosti, Photis Beris, Richard E. Clark, Philipp Le Coutre, Francois Xavier Mahon, Juan Luis Steegmann, Peter Valent, Giuseppe Saglio

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations

Abstract

Nilotinib (Tasigna®) is a more potent BCR-ABL inhibitor than imatinib and was designed to overcome imatinibs deficiencies. Nilotinib has significant efficacy in patients with chronic myeloid leukemia (CML) in chronic phase, accelerated phase and blastic phase, following imatinib failure. Based on the results of the Evaluating Nilotinib Efficacy and Safety in Clinical Trials - Newly Diagnosed Patients (ENESTnd) study, the US FDA has granted accelerated approval of nilotinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase. Imatinib has changed our perceptions of the therapeutic power of targeted inhibition of a pathologically active kinase. Nilotinib, a designer agent built on the imatinib scaffold, has proven superior to its template agent by every significant surrogate marker we use in monitoring CML. Nilotinibs clinical superiority over imatinib, as demonstrated by the ENESTnd study, has established it as an agent that we believe is a significant further step towards the cure of CML.

Original languageEnglish (US)
Pages (from-to)665-673
Number of pages9
JournalExpert Review of Hematology
Volume3
Issue number6
DOIs
StatePublished - Dec 1 2010

Keywords

  • ABL kinase inhibitors
  • ENESTnd
  • FDA approval
  • chronic myeloid leukemia
  • first-line therapy
  • imatinib
  • nilotinib

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: The ENESTnd study'. Together they form a unique fingerprint.

Cite this